Martin G. Pomper
Johns Hopkins University School of Medicine
682 Papers
3.1K Citations
Martin G. Pomper is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 80, co-authored 601 publications. Previous affiliations of Martin G. Pomper include University of Illinois at Chicago & Johns Hopkins University.
Chat about Author
Papers
Journal Article
Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it.
Steven P. Rowe,Andrew F. Voter,Rudolf A. Werner,Katherine Zukotynski,Martin G. Pomper,Michael A. Gorin,Lilja B. Solnes +6 more
TL;DR: The first commercial PSMA PET agent, 18F-DCFPyL (piflu-folastat F 18), was introduced in 2014 as discussed by the authors , and its regulatory approval hinged upon two key, multi-center, registration trials, OSPREY (patient population: highrisk primary staging) and CONDOR (patient populations: biochemical recurrence).
1
Patent
Psma-targeted pamam dendrimers for specific delivery of imaging, contrast and therapeutic agents
Martin G. Pomper,Wojciech G. Lesniak,Srikanth Boinapally,Sangeeta Ray,Foss Cathrine A +4 more
- 18 Jun 2020
TL;DR: Prostate-specific membrane antigen (PSMA)-targeted PAMAM dendrimers (G4-PSMA) and their use for imaging or treating PSMA-expressing tumors or cells are disclosed in this article.
1
Multi-timepoint imaging with PSMA-targeted [^18F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging
Sara Sheikhbahaei,Ricardo Bello Martinez,Mark C. Markowski,Mario A. Eisenberger,Kenneth J. Pienta,Diane K. Reyes,Mary Katherine Brosnan,Ergi Spiro,Rehab Abdallah,Daniel P. Holt,Robert F. Dannals,Rudolf A. Werner,Martin G. Pomper,Michael A. Gorin,Lilja B. Solnes,Steven P. Rowe +15 more
TL;DR: F-Florastamin is a promising new radioligand for PSMA-targeted PET with suitable lesion detectability and high TBR at both time points.
1